董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David J. Woodhouse | 男 | Chief Executive Officer, Acting Chief Financial Officer and Director | 50 | 209.22万美元 | 未持股 | 2020-03-31 |
| Jin Long Chen | 男 | Founder, Chief Scientific Officer and Director | 57 | 191.76万美元 | 未持股 | 2020-03-31 |
| David V. Goeddel | 男 | Director | 68 | 24.04万美元 | 未持股 | 2020-03-31 |
| David Schnell | -- | Director | 59 | 未披露 | 未持股 | 2020-03-31 |
| Mark Leschly | 男 | Director | 51 | 22.16万美元 | 未持股 | 2020-03-31 |
| William J. Rieflin | 男 | Executive Chairman of the Board and Director | 60 | 181.31万美元 | 未持股 | 2020-03-31 |
| McHenry T. Tichenor, Jr. | 男 | Director | 64 | 24.11万美元 | 未持股 | 2020-03-31 |
| David Schnell | 男 | Director | 59 | 22.54万美元 | 未持股 | 2020-03-31 |
| Suzanne Sawochka Hooper | 女 | Director | 54 | 73.03万美元 | 未持股 | 2020-03-31 |
| Shelly D. Guyer | 女 | Director | 59 | 50.39万美元 | 未持股 | 2020-03-31 |
| Suzanne Sawochka Hooper | 女 | Director | 54 | 未披露 | 未持股 | 2020-03-31 |
| Peter Svennilson | 男 | Director | 63 | 21.41万美元 | 未持股 | 2020-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David J. Woodhouse | 男 | Chief Executive Officer, Acting Chief Financial Officer and Director | 50 | 209.22万美元 | 未持股 | 2020-03-31 |
| Jin Long Chen | 男 | Founder, Chief Scientific Officer and Director | 57 | 191.76万美元 | 未持股 | 2020-03-31 |
| Hsiao D. Lieu | 男 | Senior Vice President, Chief Medical Officer | 49 | 未披露 | 未持股 | 2020-03-31 |
| William J. Rieflin | 男 | Executive Chairman of the Board and Director | 60 | 181.31万美元 | 未持股 | 2020-03-31 |
董事简历
中英对照 | 中文 | 英文- David J. Woodhouse
-
DavidJ.Woodhouse在2015年3月至2018年9月担任我们的首席财务官后，于2018年9月成为我们的首席执行官，代理首席财务官和董事会成员。从2002年到2015年，他曾担任Goldman Sachs&Co.LLC的投资银行家，最近担任梦百合投资银行集团的董事总经理兼生物技术投资银行业务联席主管。在他的职业生涯早期，Woodhouse博士曾在Dynavax Technologies工作，也曾在Amgen，Inc.担任研究助理。Woodhouse博士在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得药理学学士学位，在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得分子药理学博士学位。
David J. Woodhouse became our Chief Executive Officer, Acting Chief Financial Officer and a member of our Board of Directors in September 2018 after having served as our Chief Financial Officer from March 2015 until September 2018. From 2002 to 2015 he was an investment banker at Goldman Sachs & Co. LLC, most recently as a managing director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine. - DavidJ.Woodhouse在2015年3月至2018年9月担任我们的首席财务官后，于2018年9月成为我们的首席执行官，代理首席财务官和董事会成员。从2002年到2015年，他曾担任Goldman Sachs&Co.LLC的投资银行家，最近担任梦百合投资银行集团的董事总经理兼生物技术投资银行业务联席主管。在他的职业生涯早期，Woodhouse博士曾在Dynavax Technologies工作，也曾在Amgen，Inc.担任研究助理。Woodhouse博士在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得药理学学士学位，在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得分子药理学博士学位。
- David J. Woodhouse became our Chief Executive Officer, Acting Chief Financial Officer and a member of our Board of Directors in September 2018 after having served as our Chief Financial Officer from March 2015 until September 2018. From 2002 to 2015 he was an investment banker at Goldman Sachs & Co. LLC, most recently as a managing director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.
- Jin Long Chen
-
自2008年1月以来，Jin Long Chen一直担任我们的董事会成员和首席科学官。从2004年到2008年，Chen博士在Amgen担任多个职位，最近的职位是其Vice President，代谢研究。在加入安进之前，陈博士是图拉里克大学生物系的Vice President。他自2016年起担任Tenaya Therapeutics，Inc.的董事。陈博士在辅仁天主教大学获得学士学位，在台湾大学获得硕士学位，在加州大学伯克利分校获得博士学位。
Jin Long Chen has served as member of our board of directors since October 2016. Dr. Chen is the founder of NGM Biopharmaceuticals and has served as a member of the NGM board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as Vice President, Metabolic Disorders. Prior to joining Amgen when Amgen acquired Tularik in 2004 Dr. Chen served as Vice President of Biology at Tularik. Dr. Chen received a B.S. in nutrition and food science from Fu-Jen Catholic University and a Ph.D. in molecular and cell biology from the University of California, Berkeley. - 自2008年1月以来，Jin Long Chen一直担任我们的董事会成员和首席科学官。从2004年到2008年，Chen博士在Amgen担任多个职位，最近的职位是其Vice President，代谢研究。在加入安进之前，陈博士是图拉里克大学生物系的Vice President。他自2016年起担任Tenaya Therapeutics，Inc.的董事。陈博士在辅仁天主教大学获得学士学位，在台湾大学获得硕士学位，在加州大学伯克利分校获得博士学位。
- Jin Long Chen has served as member of our board of directors since October 2016. Dr. Chen is the founder of NGM Biopharmaceuticals and has served as a member of the NGM board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as Vice President, Metabolic Disorders. Prior to joining Amgen when Amgen acquired Tularik in 2004 Dr. Chen served as Vice President of Biology at Tularik. Dr. Chen received a B.S. in nutrition and food science from Fu-Jen Catholic University and a Ph.D. in molecular and cell biology from the University of California, Berkeley.
- David V. Goeddel
-
DavidV.Goeddel自2008年1月起担任董事会主席，并于2008年至2010年担任首席执行官，于2018年9月成为董事会首席独立董事。Goeddel博士从2007年开始一直担任The Column Group“；TCG”；的管理合伙人，这是一家风险投资合伙企业。Goeddel博士于1991年11月共同创立Tularik，1996年之前担任研究Vice President，1996年至2004年担任首席执行官。他曾担任安进公司的第一位高级科学Vice President，直到2006年5月。任职Tularik公司之前，他曾是Genentech公司聘用的第一位科学家，并担任多种职务（从1978年到1993年），包括研究员、职员科学家和分子生物学董事。Goeddel博士自2015年以来一直担任RAPTTherapeutics，Inc.的董事，该公司是一家上市的生物技术公司。他是国家科学院（National Academy of Sciences）和美国艺术与科学院（American Academy of Arts and Sciences）的成员。Goeddel博士在加州大学圣地亚哥分校（University of California，San Diego）获得化学学士学位，并在科罗拉多大学（University of Colorado）获得博士学位。
David V. Goeddel has served as a member of our board of directors since August 2016 and as a member of our compensation committee since December 2018. Dr. Goeddel has served as a Managing Partner of The Column Group, a venture capital firm, since 2007. Dr. Goeddel is a member of the board of directors at NGM Biopharmaceuticals, a public biopharmaceutical company. Additionally, Dr. Goeddel serves on the board of directors for A2 Biotherapeutics Chairman, Surrozen and Hexagon Bio (Chairman), all privately held biopharmaceutical companies. Dr. Goeddel co-founded Tularik in November 1991 was Vice President of Research until 1996 and served as Chief Executive Officer from 1996 until 2004. He then served as Amgen’s first Senior Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins was the basis for five marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Dr. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. He holds a B.A. in chemistry from the University of California, San Diego and a Ph.D. in biochemistry from the University of Colorado. - DavidV.Goeddel自2008年1月起担任董事会主席，并于2008年至2010年担任首席执行官，于2018年9月成为董事会首席独立董事。Goeddel博士从2007年开始一直担任The Column Group“；TCG”；的管理合伙人，这是一家风险投资合伙企业。Goeddel博士于1991年11月共同创立Tularik，1996年之前担任研究Vice President，1996年至2004年担任首席执行官。他曾担任安进公司的第一位高级科学Vice President，直到2006年5月。任职Tularik公司之前，他曾是Genentech公司聘用的第一位科学家，并担任多种职务（从1978年到1993年），包括研究员、职员科学家和分子生物学董事。Goeddel博士自2015年以来一直担任RAPTTherapeutics，Inc.的董事，该公司是一家上市的生物技术公司。他是国家科学院（National Academy of Sciences）和美国艺术与科学院（American Academy of Arts and Sciences）的成员。Goeddel博士在加州大学圣地亚哥分校（University of California，San Diego）获得化学学士学位，并在科罗拉多大学（University of Colorado）获得博士学位。
- David V. Goeddel has served as a member of our board of directors since August 2016 and as a member of our compensation committee since December 2018. Dr. Goeddel has served as a Managing Partner of The Column Group, a venture capital firm, since 2007. Dr. Goeddel is a member of the board of directors at NGM Biopharmaceuticals, a public biopharmaceutical company. Additionally, Dr. Goeddel serves on the board of directors for A2 Biotherapeutics Chairman, Surrozen and Hexagon Bio (Chairman), all privately held biopharmaceutical companies. Dr. Goeddel co-founded Tularik in November 1991 was Vice President of Research until 1996 and served as Chief Executive Officer from 1996 until 2004. He then served as Amgen’s first Senior Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins was the basis for five marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Dr. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. He holds a B.A. in chemistry from the University of California, San Diego and a Ph.D. in biochemistry from the University of Colorado.
- David Schnell
-
David Schnell自2008年1月以来一直担任我们的董事会成员。Schnell博士自1997年共同创立Prospect Venture Partners并担任其常务董事。在此之前，Schnell博士担任风险投资公司Kleiner Perkins Caufield&Byers的合伙人。Schnell博士曾领导多家上市和私营公司的私人投资，并担任其董事。Schnell博士曾担任Amira Pharmaceuticals，Inc.（被百时美施贵宝收购）、Gloucester Pharmaceuticals（被新基医药公司收购）、KytheraBiopharmaceuticals，Inc.（被Allergan plc收购）和Rinat Neuroscience Corporation（被辉瑞收购）等公司的董事。Schnell博士在斯坦福大学（Stanford University）获得生物科学学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得健康服务研究硕士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位。
David Schnell has served as a member of our Board of Directors since January 2008. Dr. Schnell co-founded and has been a managing director at Prospect Venture Partners since 1997. Prior to that, Dr. Schnell served as a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm. Dr. Schnell has led private investments for and served on the board of directors of numerous public and private companies. Dr. Schnell previously served on the board of directors of Amira Pharmaceuticals, Inc. acquired by Bristol-Myers Squibb, Gloucester Pharmaceuticals (acquired by Celgene Corporation), Kythera Biopharmaceuticals, Inc. (acquired by Allergan plc) and Rinat Neuroscience Corporation (acquired by Pfizer), among others. Dr. Schnell received a B.S. in Biological Sciences from Stanford University, an M.A. in Health Services Research from Stanford University School of Medicine and an M.D. from Harvard Medical School. - David Schnell自2008年1月以来一直担任我们的董事会成员。Schnell博士自1997年共同创立Prospect Venture Partners并担任其常务董事。在此之前，Schnell博士担任风险投资公司Kleiner Perkins Caufield&Byers的合伙人。Schnell博士曾领导多家上市和私营公司的私人投资，并担任其董事。Schnell博士曾担任Amira Pharmaceuticals，Inc.（被百时美施贵宝收购）、Gloucester Pharmaceuticals（被新基医药公司收购）、KytheraBiopharmaceuticals，Inc.（被Allergan plc收购）和Rinat Neuroscience Corporation（被辉瑞收购）等公司的董事。Schnell博士在斯坦福大学（Stanford University）获得生物科学学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得健康服务研究硕士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位。
- David Schnell has served as a member of our Board of Directors since January 2008. Dr. Schnell co-founded and has been a managing director at Prospect Venture Partners since 1997. Prior to that, Dr. Schnell served as a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm. Dr. Schnell has led private investments for and served on the board of directors of numerous public and private companies. Dr. Schnell previously served on the board of directors of Amira Pharmaceuticals, Inc. acquired by Bristol-Myers Squibb, Gloucester Pharmaceuticals (acquired by Celgene Corporation), Kythera Biopharmaceuticals, Inc. (acquired by Allergan plc) and Rinat Neuroscience Corporation (acquired by Pfizer), among others. Dr. Schnell received a B.S. in Biological Sciences from Stanford University, an M.A. in Health Services Research from Stanford University School of Medicine and an M.D. from Harvard Medical School.
- Mark Leschly
-
Mark Leschly，自2021年2月26日起担任ChargePoint董事会成员，此前自2009年12月起担任Legacy ChargePoint董事。自1999年7月起，Leschly先生担任投资和风险资本管理公司Rho Capital Partners，Inc.的管理合伙人。自2017年以来，Leschly先生一直担任Universal Tennis，LLC的董事长兼首席执行官，该公司是网球分析和赛事管理软件平台的开发商。自2014年以来，Leschly先生还担任Iconica LLC的所有者和管理成员，该公司主要专注于体育、媒体和技术交叉领域的投资。LESCHLY先生于2008年1月至2022年5月期间担任NGM Biopharmaceuticals，Inc.的董事。Leschly先生拥有斯坦福大学商学院的工商管理硕士学位和哈佛大学的学士学位。
Mark Leschly,has served as a member of ChargePoint's Board since February 26, 2021 and previously served as a director of Legacy ChargePoint since December 2009. Since July 1999, Mr. Leschly has served as a managing partner of Rho Capital Partners, Inc., an investment and venture capital management company. Since 2017, Mr. Leschly has been the chairman and chief executive officer of Universal Tennis, LLC, which is the developer of a software platform for tennis analytics and tournament management. Since 2014, Mr. Leschly has also been the owner and managing member of Iconica LLC, which primarily focuses on investments at the intersection of sports, media and technology. Mr. Leschly served as a director of NGM Biopharmaceuticals, Inc. from January 2008 to May 2022. Mr. Leschly holds an M.B.A. from Stanford Graduate School of Business and a B.A. from Harvard University. - Mark Leschly，自2021年2月26日起担任ChargePoint董事会成员，此前自2009年12月起担任Legacy ChargePoint董事。自1999年7月起，Leschly先生担任投资和风险资本管理公司Rho Capital Partners，Inc.的管理合伙人。自2017年以来，Leschly先生一直担任Universal Tennis，LLC的董事长兼首席执行官，该公司是网球分析和赛事管理软件平台的开发商。自2014年以来，Leschly先生还担任Iconica LLC的所有者和管理成员，该公司主要专注于体育、媒体和技术交叉领域的投资。LESCHLY先生于2008年1月至2022年5月期间担任NGM Biopharmaceuticals，Inc.的董事。Leschly先生拥有斯坦福大学商学院的工商管理硕士学位和哈佛大学的学士学位。
- Mark Leschly,has served as a member of ChargePoint's Board since February 26, 2021 and previously served as a director of Legacy ChargePoint since December 2009. Since July 1999, Mr. Leschly has served as a managing partner of Rho Capital Partners, Inc., an investment and venture capital management company. Since 2017, Mr. Leschly has been the chairman and chief executive officer of Universal Tennis, LLC, which is the developer of a software platform for tennis analytics and tournament management. Since 2014, Mr. Leschly has also been the owner and managing member of Iconica LLC, which primarily focuses on investments at the intersection of sports, media and technology. Mr. Leschly served as a director of NGM Biopharmaceuticals, Inc. from January 2008 to May 2022. Mr. Leschly holds an M.B.A. from Stanford Graduate School of Business and a B.A. from Harvard University.
- William J. Rieflin
-
William J. Rieflin自2011年3月担任董事会成员。自2010年9月他在NGM生物制药股份有限公司担任首席执行官和董事，该公司是一家生物技术公司。从2004年直到2010年他担任XenoPort股份有限公司总裁，XenoPort股份有限公司是一家生物技术公司，并主要致力于运输性前体药物的发现与开发。从1996年到2004年，他在Tularik股份有限公司担任各类职务，该公司是一家生物技术公司并主要致力于基因表达规则备的选药物产品的发现与开发，他在该公司担任的最近的职务有负责企业管理的执行副总裁、首席财务官、法律总顾问以及秘书长。Amgen股份有限公司是一家生物技术公司，该公司于2004年收购Tularik公司。Rieflin先生目前担任XenoPort股份有限公司和NGM生物制药股份有限公司董事。Rieflin先生从康奈尔大学获得学士学位，从芝加哥大学商学院获得工商管理学硕士学位，从斯坦福大学法学院获得法学博士学位。
William J. Rieflin became Executive Chairman of Ngm Biopharmaceuticals, Inc. Board of Directors in September 2018 after having served as Ngm Biopharmaceuticals, Inc. Chief Executive Officer and a member of Ngm Biopharmaceuticals, Inc. Board of Directors since September 2010. From 2004 until 2010 he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004 he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004 most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015 a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School. - William J. Rieflin自2011年3月担任董事会成员。自2010年9月他在NGM生物制药股份有限公司担任首席执行官和董事，该公司是一家生物技术公司。从2004年直到2010年他担任XenoPort股份有限公司总裁，XenoPort股份有限公司是一家生物技术公司，并主要致力于运输性前体药物的发现与开发。从1996年到2004年，他在Tularik股份有限公司担任各类职务，该公司是一家生物技术公司并主要致力于基因表达规则备的选药物产品的发现与开发，他在该公司担任的最近的职务有负责企业管理的执行副总裁、首席财务官、法律总顾问以及秘书长。Amgen股份有限公司是一家生物技术公司，该公司于2004年收购Tularik公司。Rieflin先生目前担任XenoPort股份有限公司和NGM生物制药股份有限公司董事。Rieflin先生从康奈尔大学获得学士学位，从芝加哥大学商学院获得工商管理学硕士学位，从斯坦福大学法学院获得法学博士学位。
- William J. Rieflin became Executive Chairman of Ngm Biopharmaceuticals, Inc. Board of Directors in September 2018 after having served as Ngm Biopharmaceuticals, Inc. Chief Executive Officer and a member of Ngm Biopharmaceuticals, Inc. Board of Directors since September 2010. From 2004 until 2010 he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004 he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004 most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015 a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.
- McHenry T. Tichenor, Jr.
-
McHenry T. Tichenor, Jr.是WWWW Foundation, Inc. Quad W（为纪念他的儿子成立于2007年的501（c）（3）基金会，支持高等教育和肉瘤研究的创新理念）的私人投资者和执行总监。从2003年9月到2005年1月他担任Univision Communications, Inc.（在美国领先的西班牙语媒体公司）的执行副总裁兼无线电的总裁。他担任Hispanic Broadcasting Corporation（在美国最大的西班牙语广播公司）的董事长、总裁和首席执行官（从1997年到1997年它与Univision合并）。在此之前，从1981年到1997年他担任Tichenor Media System（家族企业）的总裁。他从2003年9月到2007年服务于Univision的董事会，从2007年2月到2009年5月担任HFF, Inc.（商业房地产和资本市场服务的提供者）的董事。他是德州大学奥斯丁分校麦克库姆商学院咨询委员会（The University of Texas at Austin McCombs School of Business Advisory Council）的成员，the MD Anderson Cancer Center监事会的成员，活跃于the University of Texas at Austin的许多董事会，是NGM Biopharmaceuticals, Inc.的董事会成员。
McHenry T. Tichenor, Jr. has served as a member of our Board of Directors since March 2010. He has also served as the President of Tichenor Ventures, LLC since January 2010 and held a board observer role at Peloton Therapeutics, Inc. from October 2012 until its sale to Merck in July 2019. He served as a director of Belo Corp. from 2009 to 2013. Mr. Tichenor served as President, Chief Executive Officer and Director of Tichenor Media System, Inc. from 1981 to 1997 which he subsequently merged with the Hispanic Broadcasting Corporation and, ultimately, with Univision Communications. Mr. Tichenor currently serves as President of the Osteosarcoma Institute and the Executive Director of WWWW Foundation, Inc., non-profit organizations devoted, in part, to cancer research. From 2010 to 2018 Mr. Tichenor served as Board Chairman of the Sarcoma Alliance for Research through Collaboration, a non-profit sponsor of clinical trials for the prevention, treatment and cure of sarcomas. Mr. Tichenor earned a B.A. with Honors in Plan II and an M.B.A. from The University of Texas at Austin, and an M.S. in biotechnology from The University of Texas at Dallas. - McHenry T. Tichenor, Jr.是WWWW Foundation, Inc. Quad W（为纪念他的儿子成立于2007年的501（c）（3）基金会，支持高等教育和肉瘤研究的创新理念）的私人投资者和执行总监。从2003年9月到2005年1月他担任Univision Communications, Inc.（在美国领先的西班牙语媒体公司）的执行副总裁兼无线电的总裁。他担任Hispanic Broadcasting Corporation（在美国最大的西班牙语广播公司）的董事长、总裁和首席执行官（从1997年到1997年它与Univision合并）。在此之前，从1981年到1997年他担任Tichenor Media System（家族企业）的总裁。他从2003年9月到2007年服务于Univision的董事会，从2007年2月到2009年5月担任HFF, Inc.（商业房地产和资本市场服务的提供者）的董事。他是德州大学奥斯丁分校麦克库姆商学院咨询委员会（The University of Texas at Austin McCombs School of Business Advisory Council）的成员，the MD Anderson Cancer Center监事会的成员，活跃于the University of Texas at Austin的许多董事会，是NGM Biopharmaceuticals, Inc.的董事会成员。
- McHenry T. Tichenor, Jr. has served as a member of our Board of Directors since March 2010. He has also served as the President of Tichenor Ventures, LLC since January 2010 and held a board observer role at Peloton Therapeutics, Inc. from October 2012 until its sale to Merck in July 2019. He served as a director of Belo Corp. from 2009 to 2013. Mr. Tichenor served as President, Chief Executive Officer and Director of Tichenor Media System, Inc. from 1981 to 1997 which he subsequently merged with the Hispanic Broadcasting Corporation and, ultimately, with Univision Communications. Mr. Tichenor currently serves as President of the Osteosarcoma Institute and the Executive Director of WWWW Foundation, Inc., non-profit organizations devoted, in part, to cancer research. From 2010 to 2018 Mr. Tichenor served as Board Chairman of the Sarcoma Alliance for Research through Collaboration, a non-profit sponsor of clinical trials for the prevention, treatment and cure of sarcomas. Mr. Tichenor earned a B.A. with Honors in Plan II and an M.B.A. from The University of Texas at Austin, and an M.S. in biotechnology from The University of Texas at Dallas.
- David Schnell
-
David Schnell自2006年5月起担任Kythera Biopharmaceuticals, Inc.董事会成员。自1997年以来，Schnell博士共同创立了风险投资公司Prospect Venture Partners并担任其董事总经理。在此之前，Schnell博士曾担任风险投资公司Kleiner Perkins Caufield & Byers KPCB的合伙人。在加入KPCB之前，Schnell博士曾在美国和瑞士的Sandoz Pharmaceuticals（现为Novartis International AG）（一家制药公司）担任产品营销、战略运营和业务发展方面的多个执行管理职位。Schnell博士曾领导众多上市公司和私营公司的私人投资并在其董事会任职。Schnell博士目前在Alvine Pharmaceuticals、Ngm生物制药、Nora Therapeutics和其他几家私营公司的董事会任职。Schnell博士之前曾在Amira Pharmaceuticals（被百时美施贵宝收购）、Gloucester Pharmaceuticals（被新基医药公司收购）和Rinat Neurosciences（被辉瑞收购）等公司的董事会任职。Schnell博士获得了学士学位。斯坦福大学生物科学学士、斯坦福大学医学院健康服务研究硕士和哈佛医学院医学博士。
David Schnell has served as a member of Kythera Biopharmaceuticals, Inc.'s Board since May 2006. Dr. Schnell co-founded and has been a Managing Director at Prospect Venture Partners, a venture capital firm, since 1997. Prior to that experience, Dr. Schnell served as a Partner at Kleiner Perkins Caufield & Byers KPCB, a venture capital firm. Prior to KPCB, Dr. Schnell served in various executive management positions in product marketing, strategic operations and business development in the U.S. and Switzerland at Sandoz Pharmaceuticals (presently Novartis International AG), a pharmaceutical company. Dr. Schnell has led private investments for and served on the board of directors of numerous public and private companies. Dr. Schnell currently serves on the board of directors of Alvine Pharmaceuticals, NGM Biopharmaceuticals, Nora Therapeutics and several other privately held companies. Dr. Schnell previously served on the board of directors of Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Gloucester Pharmaceuticals (acquired by Celgene Corporation) and Rinat Neurosciences (acquired by Pfizer), among others. Dr. Schnell received a B.S. in Biological Sciences from Stanford University, a M.A. in Health Services Research from Stanford University School of Medicine, and a M.D. from Harvard Medical School. - David Schnell自2006年5月起担任Kythera Biopharmaceuticals, Inc.董事会成员。自1997年以来，Schnell博士共同创立了风险投资公司Prospect Venture Partners并担任其董事总经理。在此之前，Schnell博士曾担任风险投资公司Kleiner Perkins Caufield & Byers KPCB的合伙人。在加入KPCB之前，Schnell博士曾在美国和瑞士的Sandoz Pharmaceuticals（现为Novartis International AG）（一家制药公司）担任产品营销、战略运营和业务发展方面的多个执行管理职位。Schnell博士曾领导众多上市公司和私营公司的私人投资并在其董事会任职。Schnell博士目前在Alvine Pharmaceuticals、Ngm生物制药、Nora Therapeutics和其他几家私营公司的董事会任职。Schnell博士之前曾在Amira Pharmaceuticals（被百时美施贵宝收购）、Gloucester Pharmaceuticals（被新基医药公司收购）和Rinat Neurosciences（被辉瑞收购）等公司的董事会任职。Schnell博士获得了学士学位。斯坦福大学生物科学学士、斯坦福大学医学院健康服务研究硕士和哈佛医学院医学博士。
- David Schnell has served as a member of Kythera Biopharmaceuticals, Inc.'s Board since May 2006. Dr. Schnell co-founded and has been a Managing Director at Prospect Venture Partners, a venture capital firm, since 1997. Prior to that experience, Dr. Schnell served as a Partner at Kleiner Perkins Caufield & Byers KPCB, a venture capital firm. Prior to KPCB, Dr. Schnell served in various executive management positions in product marketing, strategic operations and business development in the U.S. and Switzerland at Sandoz Pharmaceuticals (presently Novartis International AG), a pharmaceutical company. Dr. Schnell has led private investments for and served on the board of directors of numerous public and private companies. Dr. Schnell currently serves on the board of directors of Alvine Pharmaceuticals, NGM Biopharmaceuticals, Nora Therapeutics and several other privately held companies. Dr. Schnell previously served on the board of directors of Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Gloucester Pharmaceuticals (acquired by Celgene Corporation) and Rinat Neurosciences (acquired by Pfizer), among others. Dr. Schnell received a B.S. in Biological Sciences from Stanford University, a M.A. in Health Services Research from Stanford University School of Medicine, and a M.D. from Harvard Medical School.
- Suzanne Sawochka Hooper
-
Suzanne Sawochka Hooper，2012年3月被任命为我们的执行副总裁和总顾问。从1999年至2012年初，她担任了法律公司Cooley LLP的合伙人。Hooper女士曾担任过几年的Cooley的管理委员会成员，和公司业务部门副董事长。在Cooley时， Hooper女士主攻公司法和证券法，主要是生命科学行业的公司和投资者。Hooper女士获得了伯克利University of California， 和Boalt Hall School of Law的法学博士学位，以及圣巴巴拉University of California的政治学学士学位。Hooper女士是the State Bar of California的成员。
Suzanne Sawochka Hooper was appointed our Executive Vice President and General Counsel as of March 2012. From 1999 through early 2012 she was a partner in the law firm Cooley LLP. Ms. Hooper served for several years as a member of Cooley’s Management Committee and as Vice Chair of the firm’s Business Department. While at Cooley, Ms. Hooper practiced corporate and securities law, primarily with companies and investors in the life sciences industry. Ms. Hooper received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California. - Suzanne Sawochka Hooper，2012年3月被任命为我们的执行副总裁和总顾问。从1999年至2012年初，她担任了法律公司Cooley LLP的合伙人。Hooper女士曾担任过几年的Cooley的管理委员会成员，和公司业务部门副董事长。在Cooley时， Hooper女士主攻公司法和证券法，主要是生命科学行业的公司和投资者。Hooper女士获得了伯克利University of California， 和Boalt Hall School of Law的法学博士学位，以及圣巴巴拉University of California的政治学学士学位。Hooper女士是the State Bar of California的成员。
- Suzanne Sawochka Hooper was appointed our Executive Vice President and General Counsel as of March 2012. From 1999 through early 2012 she was a partner in the law firm Cooley LLP. Ms. Hooper served for several years as a member of Cooley’s Management Committee and as Vice Chair of the firm’s Business Department. While at Cooley, Ms. Hooper practiced corporate and securities law, primarily with companies and investors in the life sciences industry. Ms. Hooper received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California.
- Shelly D. Guyer
-
Shelly D. Guyer，自2013年4月以来一直担任我们的首席财务官和秘书。在加入我们之前，从2008年4月到2012年12月，Guyer女士担任iRhythm Technologies, Inc.的财务和行政部执行副总裁兼首席财务官，这是一家医疗设备和服务的公司。从2006年3月到2007年8月，Guyer女士担任Nuvelo Inc.业务开发和投资者关系部门的副总裁，这是一家生物制药公司。加入Nuvelo Inc.之前，Guyer女士曾在J.P. Morgan Securities 及其前身公司工作超过17年，担任各种各样的角色，包括在医疗保健投资银行服务。Guyer女士持有普林斯顿大学（Princeton University ）政治学学士学位和加利福尼亚大学伯克利分校哈斯商学院（the Haas School of Business at the University of California, Berkeley）工商管理硕士学位。
Shelly D. Guyer has served as a member of our Board of Directors since December 2019. Ms. Guyer has served as the Chief Financial Officer of Invitae Corporation, a publicly-traded leading medical genetics company, since June 2017. Prior to that, she served as Chief Financial Officer of Veracyte, Inc., a genomic diagnostics company, from April 2013 to December 2016 and served as Veracyte’s Secretary from April 2013 to March 2014. From April 2008 to December 2012 she served as Chief Financial Officer and Executive Vice President of Finance and Administration of iRhythm Technologies, Inc., a digital healthcare company. From March 2006 to August 2007 Ms. Guyer served as Vice President of Business Development and Investor Relations of Nuvelo, Inc., a biopharmaceutical company. Prior to joining Nuvelo, Inc., Ms. Guyer worked at J.P. Morgan Securities and its predecessor companies for over 17 years, serving in a variety of roles including in healthcare investment banking. Ms. Guyer received an A.B. in Politics from Princeton University and an M.B.A. from the Haas School of Business at the University of California, Berkeley. - Shelly D. Guyer，自2013年4月以来一直担任我们的首席财务官和秘书。在加入我们之前，从2008年4月到2012年12月，Guyer女士担任iRhythm Technologies, Inc.的财务和行政部执行副总裁兼首席财务官，这是一家医疗设备和服务的公司。从2006年3月到2007年8月，Guyer女士担任Nuvelo Inc.业务开发和投资者关系部门的副总裁，这是一家生物制药公司。加入Nuvelo Inc.之前，Guyer女士曾在J.P. Morgan Securities 及其前身公司工作超过17年，担任各种各样的角色，包括在医疗保健投资银行服务。Guyer女士持有普林斯顿大学（Princeton University ）政治学学士学位和加利福尼亚大学伯克利分校哈斯商学院（the Haas School of Business at the University of California, Berkeley）工商管理硕士学位。
- Shelly D. Guyer has served as a member of our Board of Directors since December 2019. Ms. Guyer has served as the Chief Financial Officer of Invitae Corporation, a publicly-traded leading medical genetics company, since June 2017. Prior to that, she served as Chief Financial Officer of Veracyte, Inc., a genomic diagnostics company, from April 2013 to December 2016 and served as Veracyte’s Secretary from April 2013 to March 2014. From April 2008 to December 2012 she served as Chief Financial Officer and Executive Vice President of Finance and Administration of iRhythm Technologies, Inc., a digital healthcare company. From March 2006 to August 2007 Ms. Guyer served as Vice President of Business Development and Investor Relations of Nuvelo, Inc., a biopharmaceutical company. Prior to joining Nuvelo, Inc., Ms. Guyer worked at J.P. Morgan Securities and its predecessor companies for over 17 years, serving in a variety of roles including in healthcare investment banking. Ms. Guyer received an A.B. in Politics from Princeton University and an M.B.A. from the Haas School of Business at the University of California, Berkeley.
- Suzanne Sawochka Hooper
-
Suzanne Sawochka Hooper，2014年1月以来担任董事。Hooper女士2012年3月被任命为Jazz Pharmaceuticals公司的执行副总裁兼法律总顾问。1999年到2012年初，她是法务公司Cooley LLP的合伙人。Hooper女士担任Cooley管理委员会的成员7年了，也担任过公司商业开发事业部的副董事。在Cooley的时候，Hooper女士负责公司法和证券法，主要和在生命科学行业的公司以及投资者合作。Hooper女士拥有加州大学伯克利分校Boalt Hall法学院的法学博士学位，加州大学圣芭芭拉分校政治科学学士学位。Hooper女士是加州律师协会的一员。
Suzanne Sawochka Hooper has served as a member of our Board of Directors since August 2018. From March 2012 to March 2019 Ms. Hooper served as the Executive Vice President and General Counsel of Jazz Pharmaceuticals plc. From 1999 until February 2012 she was a partner in the law firm Cooley LLP. Ms. Hooper received a J.D. from the University of California Berkeley School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California. - Suzanne Sawochka Hooper，2014年1月以来担任董事。Hooper女士2012年3月被任命为Jazz Pharmaceuticals公司的执行副总裁兼法律总顾问。1999年到2012年初，她是法务公司Cooley LLP的合伙人。Hooper女士担任Cooley管理委员会的成员7年了，也担任过公司商业开发事业部的副董事。在Cooley的时候，Hooper女士负责公司法和证券法，主要和在生命科学行业的公司以及投资者合作。Hooper女士拥有加州大学伯克利分校Boalt Hall法学院的法学博士学位，加州大学圣芭芭拉分校政治科学学士学位。Hooper女士是加州律师协会的一员。
- Suzanne Sawochka Hooper has served as a member of our Board of Directors since August 2018. From March 2012 to March 2019 Ms. Hooper served as the Executive Vice President and General Counsel of Jazz Pharmaceuticals plc. From 1999 until February 2012 she was a partner in the law firm Cooley LLP. Ms. Hooper received a J.D. from the University of California Berkeley School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California.
- Peter Svennilson
-
Peter Svennilson，曾担任Carmot Therapeutics Inc.的成员。自2020年3月起担任董事会成员。他曾担任风险投资公司the Column Group, LLC(2007年成立以来)的创始人和管理合伙人。Svennilson先生曾担任上市生物制药公司PTC Therapeutics, Inc.(2012年至2014年)、Immune Design Corp.(2014年至2018年)、Gritstone bio, Inc.(2015年9月至2019年9月)和Constellation Pharmaceuticals, Inc.(2016年6月至2019年6月)、Revolution Medicines, Inc.(2020年6月至2021年6月)、ORIC Pharmaceuticals, Inc.(2014年8月至2021年8月)、RAPT Therapeutics, Inc.(2020年4月至2021年6月)的董事会成员。2008年1月至2020年5月担任NGM biopharpharmaceuticals, Inc.的董事。此前，他从2013年起担任Seragon Pharmaceuticals Inc.的董事会主席，直到该公司于2014年被Genentech, Inc.收购。他从2009年起担任Aragon Pharmaceuticals Inc.的董事会主席，直到该公司于2013年被强生公司收购。从1996年到2006年，他是Three Crowns Capital(生物技术风险投资公司)的创始人和管理合伙人。他持有the Stockholm School of Economics and Finance的学士学位和工商管理硕士学位。
Peter Svennilson,has served as a member of Carmot Therapeutics Inc. Board of Directors since March 2020. Mr. Svennilson has served as a founder and managing partner of the venture capital firm, The Column Group, LLC since its inception in 2007. Mr. Svennilson served as a board member of the publicly traded biopharmaceutical companies, PTC Therapeutics, Inc. from 2012 until 2014, Immune Design Corp. from 2014 until 2018, Gritstone bio, Inc. from September 2015 until September 2019 and Constellation Pharmaceuticals, Inc. from June 2016 until June 2019, Revolution Medicines, Inc. from June 2020 to June 2021, ORIC Pharmaceuticals, Inc. from August 2014 to August 2021, RAPT Therapeutics, Inc. from April 2020 to June 2021, and NGM Biopharmaceuticals, Inc. from January 2008 to May 2020. Previously, he served as Chairman of the board of directors of Seragon Pharmaceuticals Inc. from 2013 until it was acquired by Genentech, Inc. in 2014. He was the Chairman of the board of directors of Aragon Pharmaceuticals Inc. from 2009 until it was acquired by Johnson & Johnson in 2013. From 1996 to 2006, he was the founder and managing partner of Three Crowns Capital, a biotechnology venture capital firm. Mr. Svennilson received a B.S. and an M.B.A. from the Stockholm School of Economics and Finance. - Peter Svennilson，曾担任Carmot Therapeutics Inc.的成员。自2020年3月起担任董事会成员。他曾担任风险投资公司the Column Group, LLC(2007年成立以来)的创始人和管理合伙人。Svennilson先生曾担任上市生物制药公司PTC Therapeutics, Inc.(2012年至2014年)、Immune Design Corp.(2014年至2018年)、Gritstone bio, Inc.(2015年9月至2019年9月)和Constellation Pharmaceuticals, Inc.(2016年6月至2019年6月)、Revolution Medicines, Inc.(2020年6月至2021年6月)、ORIC Pharmaceuticals, Inc.(2014年8月至2021年8月)、RAPT Therapeutics, Inc.(2020年4月至2021年6月)的董事会成员。2008年1月至2020年5月担任NGM biopharpharmaceuticals, Inc.的董事。此前，他从2013年起担任Seragon Pharmaceuticals Inc.的董事会主席，直到该公司于2014年被Genentech, Inc.收购。他从2009年起担任Aragon Pharmaceuticals Inc.的董事会主席，直到该公司于2013年被强生公司收购。从1996年到2006年，他是Three Crowns Capital(生物技术风险投资公司)的创始人和管理合伙人。他持有the Stockholm School of Economics and Finance的学士学位和工商管理硕士学位。
- Peter Svennilson,has served as a member of Carmot Therapeutics Inc. Board of Directors since March 2020. Mr. Svennilson has served as a founder and managing partner of the venture capital firm, The Column Group, LLC since its inception in 2007. Mr. Svennilson served as a board member of the publicly traded biopharmaceutical companies, PTC Therapeutics, Inc. from 2012 until 2014, Immune Design Corp. from 2014 until 2018, Gritstone bio, Inc. from September 2015 until September 2019 and Constellation Pharmaceuticals, Inc. from June 2016 until June 2019, Revolution Medicines, Inc. from June 2020 to June 2021, ORIC Pharmaceuticals, Inc. from August 2014 to August 2021, RAPT Therapeutics, Inc. from April 2020 to June 2021, and NGM Biopharmaceuticals, Inc. from January 2008 to May 2020. Previously, he served as Chairman of the board of directors of Seragon Pharmaceuticals Inc. from 2013 until it was acquired by Genentech, Inc. in 2014. He was the Chairman of the board of directors of Aragon Pharmaceuticals Inc. from 2009 until it was acquired by Johnson & Johnson in 2013. From 1996 to 2006, he was the founder and managing partner of Three Crowns Capital, a biotechnology venture capital firm. Mr. Svennilson received a B.S. and an M.B.A. from the Stockholm School of Economics and Finance.
高管简历
中英对照 | 中文 | 英文- David J. Woodhouse
DavidJ.Woodhouse在2015年3月至2018年9月担任我们的首席财务官后，于2018年9月成为我们的首席执行官，代理首席财务官和董事会成员。从2002年到2015年，他曾担任Goldman Sachs&Co.LLC的投资银行家，最近担任梦百合投资银行集团的董事总经理兼生物技术投资银行业务联席主管。在他的职业生涯早期，Woodhouse博士曾在Dynavax Technologies工作，也曾在Amgen，Inc.担任研究助理。Woodhouse博士在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得药理学学士学位，在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得分子药理学博士学位。
David J. Woodhouse became our Chief Executive Officer, Acting Chief Financial Officer and a member of our Board of Directors in September 2018 after having served as our Chief Financial Officer from March 2015 until September 2018. From 2002 to 2015 he was an investment banker at Goldman Sachs & Co. LLC, most recently as a managing director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.- DavidJ.Woodhouse在2015年3月至2018年9月担任我们的首席财务官后，于2018年9月成为我们的首席执行官，代理首席财务官和董事会成员。从2002年到2015年，他曾担任Goldman Sachs&Co.LLC的投资银行家，最近担任梦百合投资银行集团的董事总经理兼生物技术投资银行业务联席主管。在他的职业生涯早期，Woodhouse博士曾在Dynavax Technologies工作，也曾在Amgen，Inc.担任研究助理。Woodhouse博士在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得药理学学士学位，在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得分子药理学博士学位。
- David J. Woodhouse became our Chief Executive Officer, Acting Chief Financial Officer and a member of our Board of Directors in September 2018 after having served as our Chief Financial Officer from March 2015 until September 2018. From 2002 to 2015 he was an investment banker at Goldman Sachs & Co. LLC, most recently as a managing director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.
- Jin Long Chen
自2008年1月以来，Jin Long Chen一直担任我们的董事会成员和首席科学官。从2004年到2008年，Chen博士在Amgen担任多个职位，最近的职位是其Vice President，代谢研究。在加入安进之前，陈博士是图拉里克大学生物系的Vice President。他自2016年起担任Tenaya Therapeutics，Inc.的董事。陈博士在辅仁天主教大学获得学士学位，在台湾大学获得硕士学位，在加州大学伯克利分校获得博士学位。
Jin Long Chen has served as member of our board of directors since October 2016. Dr. Chen is the founder of NGM Biopharmaceuticals and has served as a member of the NGM board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as Vice President, Metabolic Disorders. Prior to joining Amgen when Amgen acquired Tularik in 2004 Dr. Chen served as Vice President of Biology at Tularik. Dr. Chen received a B.S. in nutrition and food science from Fu-Jen Catholic University and a Ph.D. in molecular and cell biology from the University of California, Berkeley.- 自2008年1月以来，Jin Long Chen一直担任我们的董事会成员和首席科学官。从2004年到2008年，Chen博士在Amgen担任多个职位，最近的职位是其Vice President，代谢研究。在加入安进之前，陈博士是图拉里克大学生物系的Vice President。他自2016年起担任Tenaya Therapeutics，Inc.的董事。陈博士在辅仁天主教大学获得学士学位，在台湾大学获得硕士学位，在加州大学伯克利分校获得博士学位。
- Jin Long Chen has served as member of our board of directors since October 2016. Dr. Chen is the founder of NGM Biopharmaceuticals and has served as a member of the NGM board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as Vice President, Metabolic Disorders. Prior to joining Amgen when Amgen acquired Tularik in 2004 Dr. Chen served as Vice President of Biology at Tularik. Dr. Chen received a B.S. in nutrition and food science from Fu-Jen Catholic University and a Ph.D. in molecular and cell biology from the University of California, Berkeley.
- Hsiao D. Lieu
Xiao D.Lieu于2019年3月加入NGM，担任高级副总裁，首席医疗官。在NGM之前，Lieu博士于2017年11月至2019年3月在Genentech工作，担任所有非肿瘤分子早期临床开发的Vice President。他还曾于2012年7月至2017年11月在礼来公司工作，担任多个领导职务，最近担任AutoImmune，Taltz®；的全球品牌开发负责人。在加入礼来公司之前，Lieu博士是Retinorx，LLC的联合创始人兼首席执行官，Niles Therapeutics，Inc.的首席医疗官兼执行Vice President，并在被Gilead收购的PortolaPharmaceuticals，Inc.和CV Therapeutics，Inc.担任临床开发领导职务。Lieu博士从2002年到2013年是旧金山综合医院（San Francisco General Hospital）的主治心脏病专家，也是加州大学旧金山分校（University of California，San Francisco）的兼职临床医学副教授。Lieu博士在阿尔伯特·爱因斯坦医学院（Albert Einstein College of Medicine）获得医学博士学位，在纽约大学（New York University）获得工商管理硕士学位。
Hsiao D. Lieu joined NGM in March 2019 as Senior Vice President, Chief Medical Officer. Prior to NGM, Dr. Lieu worked at Genentech from November 2017 to March 2019 as Vice President of Early Clinical Development for all non-oncology molecules. He also worked at Eli Lilly and Company from July 2012 through November 2017 where he held various leadership roles, most recently as Global Brand Development Leader, Autoimmune, Taltz®. Prior to joining Eli Lilly and Company, Dr. Lieu was a co-founder and Chief Executive Officer of RetinoRx, LLC, Chief Medical Officer and Executive Vice President at Niles Therapeutics, Inc. and held clinical development leadership roles with Portola Pharmaceuticals, Inc. and CV Therapeutics, Inc. acquired by Gilead. Dr. Lieu was an attending cardiologist at San Francisco General Hospital from 2002 to 2013 and an adjunct Associate Clinical Medical Professor at University of California, San Francisco. Dr. Lieu received his M.D. from Albert Einstein College of Medicine and B.A. from New York University.- Xiao D.Lieu于2019年3月加入NGM，担任高级副总裁，首席医疗官。在NGM之前，Lieu博士于2017年11月至2019年3月在Genentech工作，担任所有非肿瘤分子早期临床开发的Vice President。他还曾于2012年7月至2017年11月在礼来公司工作，担任多个领导职务，最近担任AutoImmune，Taltz®；的全球品牌开发负责人。在加入礼来公司之前，Lieu博士是Retinorx，LLC的联合创始人兼首席执行官，Niles Therapeutics，Inc.的首席医疗官兼执行Vice President，并在被Gilead收购的PortolaPharmaceuticals，Inc.和CV Therapeutics，Inc.担任临床开发领导职务。Lieu博士从2002年到2013年是旧金山综合医院（San Francisco General Hospital）的主治心脏病专家，也是加州大学旧金山分校（University of California，San Francisco）的兼职临床医学副教授。Lieu博士在阿尔伯特·爱因斯坦医学院（Albert Einstein College of Medicine）获得医学博士学位，在纽约大学（New York University）获得工商管理硕士学位。
- Hsiao D. Lieu joined NGM in March 2019 as Senior Vice President, Chief Medical Officer. Prior to NGM, Dr. Lieu worked at Genentech from November 2017 to March 2019 as Vice President of Early Clinical Development for all non-oncology molecules. He also worked at Eli Lilly and Company from July 2012 through November 2017 where he held various leadership roles, most recently as Global Brand Development Leader, Autoimmune, Taltz®. Prior to joining Eli Lilly and Company, Dr. Lieu was a co-founder and Chief Executive Officer of RetinoRx, LLC, Chief Medical Officer and Executive Vice President at Niles Therapeutics, Inc. and held clinical development leadership roles with Portola Pharmaceuticals, Inc. and CV Therapeutics, Inc. acquired by Gilead. Dr. Lieu was an attending cardiologist at San Francisco General Hospital from 2002 to 2013 and an adjunct Associate Clinical Medical Professor at University of California, San Francisco. Dr. Lieu received his M.D. from Albert Einstein College of Medicine and B.A. from New York University.
- William J. Rieflin
William J. Rieflin自2011年3月担任董事会成员。自2010年9月他在NGM生物制药股份有限公司担任首席执行官和董事，该公司是一家生物技术公司。从2004年直到2010年他担任XenoPort股份有限公司总裁，XenoPort股份有限公司是一家生物技术公司，并主要致力于运输性前体药物的发现与开发。从1996年到2004年，他在Tularik股份有限公司担任各类职务，该公司是一家生物技术公司并主要致力于基因表达规则备的选药物产品的发现与开发，他在该公司担任的最近的职务有负责企业管理的执行副总裁、首席财务官、法律总顾问以及秘书长。Amgen股份有限公司是一家生物技术公司，该公司于2004年收购Tularik公司。Rieflin先生目前担任XenoPort股份有限公司和NGM生物制药股份有限公司董事。Rieflin先生从康奈尔大学获得学士学位，从芝加哥大学商学院获得工商管理学硕士学位，从斯坦福大学法学院获得法学博士学位。
William J. Rieflin became Executive Chairman of Ngm Biopharmaceuticals, Inc. Board of Directors in September 2018 after having served as Ngm Biopharmaceuticals, Inc. Chief Executive Officer and a member of Ngm Biopharmaceuticals, Inc. Board of Directors since September 2010. From 2004 until 2010 he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004 he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004 most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015 a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.- William J. Rieflin自2011年3月担任董事会成员。自2010年9月他在NGM生物制药股份有限公司担任首席执行官和董事，该公司是一家生物技术公司。从2004年直到2010年他担任XenoPort股份有限公司总裁，XenoPort股份有限公司是一家生物技术公司，并主要致力于运输性前体药物的发现与开发。从1996年到2004年，他在Tularik股份有限公司担任各类职务，该公司是一家生物技术公司并主要致力于基因表达规则备的选药物产品的发现与开发，他在该公司担任的最近的职务有负责企业管理的执行副总裁、首席财务官、法律总顾问以及秘书长。Amgen股份有限公司是一家生物技术公司，该公司于2004年收购Tularik公司。Rieflin先生目前担任XenoPort股份有限公司和NGM生物制药股份有限公司董事。Rieflin先生从康奈尔大学获得学士学位，从芝加哥大学商学院获得工商管理学硕士学位，从斯坦福大学法学院获得法学博士学位。
- William J. Rieflin became Executive Chairman of Ngm Biopharmaceuticals, Inc. Board of Directors in September 2018 after having served as Ngm Biopharmaceuticals, Inc. Chief Executive Officer and a member of Ngm Biopharmaceuticals, Inc. Board of Directors since September 2010. From 2004 until 2010 he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004 he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004 most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015 a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.